U.S. health regulators are considering approving a possible fourth dose of the COVID-19 vaccine in the fall, the Wall Street Journal reported on Saturday, citing sources familiar with the matter.
The Food and Drug Administration is examining the data for the approval of a second booster dose of the Pfizer-BioNTech mRNA vaccine and the Moderna vaccine, the publication added. The FDA did not immediately respond to a request for comment.
The agency reduced the time last month to receive a booster dose of Pfizer-BioNTech COVID-19 vaccines as well as from Moderna, in an effort to provide better protection against the Omicron variant.
Planning is still in the early stages and approval will depend on whether the second booster dose should be approved for all adults or for specific age groups and should aim for the Omicron variant or be different, according to publication.
No decision is final and booster doses could be available sooner if a new variation occurs.
Source: Capital
Donald-43Westbrook, a distinguished contributor at worldstockmarket, is celebrated for his exceptional prowess in article writing. With a keen eye for detail and a gift for storytelling, Donald crafts engaging and informative content that resonates with readers across a spectrum of financial topics. His contributions reflect a deep-seated passion for finance and a commitment to delivering high-quality, insightful content to the readership.
